CMG Pharma: Q1 2026 Revenue Grows but Operating Loss Widens

Consolidated Q1 2026 revenue KRW 25.5B (up 23.7% YoY), operating loss KRW 2.9B (wider than KRW 1.3B loss a year ago)
Net profit of KRW 0.1B (vs. net loss of KRW 1.6B a year ago), boosted by FX gains and other financial income of KRW 3.3B
FDA approval for Aripiprazole ODF (Mezofy) in April 2025, targeting US market entry
Total assets KRW 319.3B, debt-to-equity ratio 58.3%, cash and equivalents KRW 9.2B
Construction in progress KRW 94.3B (CDMO facilities), long-term borrowings KRW 41.5B, current convertible bonds KRW 45.7B (8th CB: KRW 43.8B)
Allowance for doubtful accounts KRW 2.3B (6.4% of trade receivables), two ongoing lawsuits totaling KRW 1.07B
Loans to associate Matica Holdings KRW 24.2B (loss allowance KRW 7.2B), accumulated equity method losses
EPS (consolidated) KRW 1, (separate) KRW 1 (vs. KRW -11 and KRW -12 a year ago)
No dividend plan, no share buyback or cancellation